Share
In another image, a beaming Athena, dressed in a light blue jumper, poses with a white dog, thought to be the family s pet.
Athena is tenth in the line of succession to the Danish throne. She is the daughter of Prince Joachim, 51, and Princess Marie of Denmark, 44.
The young royal (pictured) sported a beaming smile when enjoying a frolic in the snow in Paris, where she lives with her parents Prince Joachim and Princess Marie, and her 12-year-old brother Prince Henrik
In two of the four photographs shared, the princess made sure to wrap up warm against the chilly weather by donning a light puffer coat and adorable pink earmuffs (pictured)
EG: Leisure Property Leads the Way in 2020 Sector Enquiries
EG: Leisure Property Leads the Way in 2020 Sector Enquiries Enquiry data gathered from EG Propertylink shows that while the first lockdown of 2020 dramatically impacted enquiries for commercial property it was searches for leisure and retail space which saw the biggest increase once restrictions started to lift.
Key findings from the report include: – Between the first and second lockdown (June to October) enquiries for property in the leisure sector rose by 64%. This was closely followed by retail and office enquiries which grew by 62% and 56% respectively. – Enquiry data for 3 out of 4 key London commuter towns examined in the report shows that enquiries for retail property as a proportion of total property searches increased in November compared to January.
(Paris:TNG)
(Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that a first patient with head and neck cancer has been dosed with the Company’s innovative individualized immunotherapy, TG4050. This novel therapeutic vaccine is based on Transgene’s
myvac® technology platform, which leverages cutting-edge Artificial Intelligence (AI) capabilities to customize the treatment for each patient.
This innovative approach combines Transgene’s expertise in virus-based immunotherapies, NEC’s longstanding AI technologies and the commitment of prestigious cancer care centers.
THE FIRST PATIENT HAS BEEN DOSED AT THE IUCT ONCOPOLE IN TOULOUSE, France,
Transgene (Paris:TNG)
(Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that a first patient with head and neck cancer has been dosed with the Company’s innovative individualized immunotherapy, TG4050. This novel therapeutic vaccine is based on Transgene’s
myvac® technology platform, which leverages cutting-edge Artificial Intelligence (AI) capabilities to customize the treatment for each patient.
This innovative approach combines Transgene’s expertise in virus-based immunotherapies, NEC’s longstanding AI technologies and the commitment of prestigious cancer care centers.
THE FIRST PATIENT HAS BEEN DOSED AT THE IUCT ONCOPOLE IN TOULOUSE, France,